ZA927010B - Method or treating immunoinflammatory disease - Google Patents

Method or treating immunoinflammatory disease

Info

Publication number
ZA927010B
ZA927010B ZA927010A ZA927010A ZA927010B ZA 927010 B ZA927010 B ZA 927010B ZA 927010 A ZA927010 A ZA 927010A ZA 927010 A ZA927010 A ZA 927010A ZA 927010 B ZA927010 B ZA 927010B
Authority
ZA
South Africa
Prior art keywords
medicament
treating immunoinflammatory
pref
immunoinflammatory disease
treating
Prior art date
Application number
ZA927010A
Other languages
English (en)
Inventor
Craig Eugene Caufield
John Henry Musser
Surendra Nath Sehgal
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of ZA927010B publication Critical patent/ZA927010B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA927010A 1991-09-17 1992-09-14 Method or treating immunoinflammatory disease ZA927010B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76112091A 1991-09-17 1991-09-17

Publications (1)

Publication Number Publication Date
ZA927010B true ZA927010B (en) 1994-03-14

Family

ID=25061205

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA927010A ZA927010B (en) 1991-09-17 1992-09-14 Method or treating immunoinflammatory disease

Country Status (23)

Country Link
US (1) US5286730A (es)
EP (1) EP0533433B1 (es)
JP (1) JP2810599B2 (es)
KR (1) KR100299394B1 (es)
AT (1) ATE151289T1 (es)
AU (1) AU659868B2 (es)
CA (1) CA2078379C (es)
CZ (1) CZ281900B6 (es)
DE (1) DE69218864T2 (es)
DK (1) DK0533433T3 (es)
ES (1) ES2100297T3 (es)
GR (1) GR3023680T3 (es)
HK (1) HK108697A (es)
HU (1) HU211112B (es)
IL (3) IL103189A (es)
MX (1) MX9205202A (es)
NZ (2) NZ328124A (es)
PH (1) PH30270A (es)
SG (1) SG43126A1 (es)
SK (1) SK279521B6 (es)
TW (1) TW212759B (es)
UA (1) UA27742C2 (es)
ZA (1) ZA927010B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
JP2741285B2 (ja) * 1992-05-22 1998-04-15 千寿製薬株式会社 緑内障治療剤
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
AT408520B (de) * 1993-05-27 2001-12-27 Novartis Erfind Verwalt Gmbh Galenische formulierungen
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
WO1996006847A1 (en) * 1994-08-31 1996-03-07 Pfizer Inc. Process for preparing demethylrapamycins
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5912224A (en) * 1996-02-22 1999-06-15 The General Hospital Corporation Methods and compositions for enhancing cellular response to TGF-β ligands
CA2261666C (en) * 1996-07-30 2010-09-14 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, autoimmune or inflammatory conditions comprising cyclosporin a and 40-0-(2-hydroxiethyl)-rapamycin
JP2001503061A (ja) * 1996-10-31 2001-03-06 アメリカン・ホーム・プロダクツ・コーポレイション ラパマイシンおよびカルシトリオールを含んでなる相乗組成物
DE19844397A1 (de) * 1998-09-28 2000-03-30 Hilti Ag Abrasive Schneidkörper enthaltend Diamantpartikel und Verfahren zur Herstellung der Schneidkörper
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
KR20020050135A (ko) * 2000-12-20 2002-06-26 조명재 피부 주름 예방 및 완화를 목적으로 하는 피부 외용 조성물
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04001524A (es) 2001-08-22 2004-05-31 Wyeth Corp 29-enoles de rapamicina.
WO2003018574A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
US6641611B2 (en) * 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
DK1553940T3 (da) 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
EP1389480A1 (en) * 2002-08-14 2004-02-18 Mondobiotech Interferon SA Therapeutical use of guanylhydrazones for the inhibition of CD83 dependent processes and dendritic cell maturation
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2007511521A (ja) * 2003-11-13 2007-05-10 コンビナトアールエックス インコーポレーティッド 炎症性障害を治療する方法および試薬
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
EA015922B1 (ru) 2005-11-14 2011-12-30 Ариад Фармасьютикалз, Инк. ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
US20100081681A1 (en) * 2006-08-16 2010-04-01 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
BRPI0718540A2 (pt) * 2006-11-07 2013-11-19 Alcon Res Ltd Método de tratamento de asma, rinite alérgica, e distúrbios de pele
WO2008063563A2 (en) * 2006-11-16 2008-05-29 Transderm, Inc. Methods of treating keratin hyperproliferation disorders using mtor inhibitors
WO2010040064A1 (en) * 2008-10-03 2010-04-08 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
KR20120061081A (ko) 2009-04-10 2012-06-12 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
ES2797376T3 (es) 2013-01-24 2020-12-02 Palvella Therapeutics Inc Composiciones para la administración transdérmica de inhibidores de mTOR
US10293010B2 (en) * 2013-10-14 2019-05-21 Izun Pharmaceuticals Corporation Methods for treatment of m-TOR inhibitor-associated stomatitis
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
US20160184279A1 (en) * 2014-12-10 2016-06-30 Transderm, Inc. METHODS OF TREATING PAIN AND/OR ITCH WITH SMALL MOLECULE INHIBITORS TARGETING AN mTOR PATHWAY
EP3352755A4 (en) 2015-09-24 2019-04-03 Drexel University Novel Compositions and Methods for the Treatment and Prevention of Skin Diseases
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
US10456383B2 (en) * 2017-06-01 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted approach in the management of Epidermolysis bullosa
JP2021530463A (ja) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物および使用方法
BR112021003497A2 (pt) * 2018-08-30 2021-05-18 Chemistryrx. composições contendo sirolimo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4023264A (en) * 1976-06-21 1977-05-17 Littelfuse, Inc. Method of making miniature plug-in fuses of different fuse ratings
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
DE69129459T2 (de) * 1990-08-10 1998-10-15 Anormed Inc Immunosuppressive zusammensetzungen
US5023262A (en) * 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
HU211112B (en) 1995-10-30
IL117640A0 (en) 1996-07-23
ES2100297T3 (es) 1997-06-16
EP0533433B1 (en) 1997-04-09
CZ278592A3 (en) 1993-04-14
KR100299394B1 (ko) 2001-10-22
JP2810599B2 (ja) 1998-10-15
IL103189A (en) 1996-08-04
JPH05194529A (ja) 1993-08-03
EP0533433A1 (en) 1993-03-24
DK0533433T3 (da) 1997-05-12
SK278592A3 (en) 1995-03-08
CZ281900B6 (cs) 1997-03-12
ATE151289T1 (de) 1997-04-15
US5286730A (en) 1994-02-15
HK108697A (en) 1997-08-22
IL117640A (en) 1999-08-17
DE69218864D1 (de) 1997-05-15
IL103189A0 (en) 1993-02-21
SG43126A1 (en) 1997-10-17
AU2450792A (en) 1993-03-18
NZ244340A (en) 1999-06-29
UA27742C2 (uk) 2000-10-16
CA2078379C (en) 2003-07-29
GR3023680T3 (en) 1997-09-30
TW212759B (es) 1993-09-11
NZ328124A (en) 2000-01-28
PH30270A (en) 1997-02-20
DE69218864T2 (de) 1997-07-17
HUT64846A (en) 1994-03-28
HU9202955D0 (en) 1992-12-28
AU659868B2 (en) 1995-06-01
CA2078379A1 (en) 1993-03-18
SK279521B6 (sk) 1998-12-02
MX9205202A (es) 1993-03-01

Similar Documents

Publication Publication Date Title
ZA927010B (en) Method or treating immunoinflammatory disease
ES2168302T3 (es) Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
EP0345302A4 (en) LIPOSOMIC VESICLES FOR THE INTRAPERITONEAL ADMINISTRATION OF THERAPEUTIC AGENTS.
HK1009939A1 (en) Medicament for treating cardiac inflammatory diseases
ES2184808T3 (es) Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.
IE893840L (en) Use of acetyl d-carnitines for treating glaucoma
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
GR3034186T3 (en) 3,4-diarylchromans for treatment of dermatitis
LT97135A (en) Use of melatonin in the manufacture of a medicament for treating patients suffering from drug addiction
PL342099A1 (en) Therapeutic agents
HK1022269A1 (en) Use of 1-hydroxy-2-pyridones in the manufacture of a medicament for treating skin infections
IT1293583B1 (it) Uso dell'acido gammaidrossibutirrico per il trattamento delle sindromi demenziali
NZ307601A (en) Use of a pharmaceutically acceptable oxalate derivative in the manufacture of a medicament for the treatment of skin conditions
NO990450L (no) Behandling av sinnslidelser
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
CA2142862A1 (en) Method for Inhibiting HIV Replication Using IL-4
AU4250697A (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
IL128494A0 (en) Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
HUP0004647A2 (hu) Glükóz-amino-glükánok alkalmazása diabétesszel társult szembetegségek kezelésére szolgáló gyógyszerkészítmények előállítására
WO1996029076A3 (en) Treatment of inflammatory bowel disorders with cotinine
AU6258798A (en) Facilitation of repair of neural injury with cm101/gbs toxin
MX9800365A (es) Tratamiento de leucemia aguda con interleucina-10.
AU4391196A (en) A transdermal therapeutic system for the administration of (s)-3-methyl-5-(1-methyl-2-pyrrolidinyl)-isoxazole or one of its pharmaceutically acceptable salts
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses
EP0872238A3 (en) Use of olanzapine for the manufacture of a medicament for neuroprotection